Bayer AG on Monday faced a second U.S. jury over allegations that its popular glyphosate-based weed killer Roundup causes cancer, six months after the company’s share price was rocked by a $289 million verdict in California state court.
The lawsuit by California resident Edwin Hardeman against the company began on Monday morning in federal rather than state court. The trial is also a test case for a larger litigation. More than 760 of the 9,300 Roundup cases nationwide are consolidated in the federal court in San Francisco that is hearing Hardeman’s case.
Bayer denies all allegations that Roundup or glyphosate cause cancer, saying decades of independent studies have shown the world’s most widely used weed killer to be safe for human use and noting that regulators around the world have approved the product.
During the first phase in the trial, the nine-person jury is asked to weigh scientific evidence to determine whether Roundup caused Hardeman’s cancer.
Aimee Wagstaff, a lawyer for Hardeman, told a packed courtroom during her opening statement on Monday that chemicals in Roundup made the weed killer more toxic than glyphosate alone, causing the man’s cancer.
But U.S. District Judge Vince Chhabria, who presides over the federal litigation, repeatedly scolded her for “crossing the line” by referring to internal corporate communications the judge has said have no bearing on the science in the case.
“You completely disregarded the limitations,” Chhabria said.
In a January ruling, Chhabria called evidence by plaintiffs that the company allegedly attempted to influence regulators and manipulate public opinion “a distraction” from the scientific question of whether glyphosate causes cancer.
If the jury determines Roundup caused Hardeman’s cancer, the judge said such evidence could be presented in a second trial phase.
Plaintiffs criticized Chhabria’s order dividing the trial and restricting evidence as “unfair,” saying their scientific evidence allegedly showing glyphosate causes cancer is inextricably linked to Monsanto’s alleged wrongful conduct.
Evidence of corporate misconduct was seen as playing a key role in the finding by a California state court jury in August that Roundup caused another man’s non-Hodgkin’s lymphoma and that Bayer’s Monsanto unit failed to warn consumers about the weed killer’s cancer risks. That jury’s $289 million damages award was later reduced to $78 million.
Bayer’s share price dropped 10 percent following the verdict and has remained volatile.
Hardeman began using the Roundup brand herbicide with glyphosate in the 1980s to control poison oak and weeds on his property and sprayed “large volumes” of the chemical for many years on a regular basis, according to court documents. He was diagnosed with non-Hodgkin’s lymphoma, a cancer of the lymph system, in February 2015 and filed his lawsuit a year later.
But Hardeman has a history of hepatitis C, a risk factor for developing lymphoma. Bayer in court filings also said the majority of non-Hodgkin’s lymphoma incidents are idiopathic, or have no known cause.
Reporting by Jim Christie in San Francisco, Writing by Tina Bellon; editing by Anthony Lin and Lisa Shumamker
Ukraine begged Trump to raise issue of their captive sailors with Putin — he didn’t and Russia state TV gloated
The ongoing impeachment inquiry into President Donald Trump is being painted by Congress and the press against the backdrop of the ongoing war between Russia and the Ukraine.
As more and more sworn deposition transcripts are released, researchers are able to link up the testimony of events with real-time reactions, giving us a remarkable insight into the implications of foreign policy decisions.
Investigative journalist Julia Davis flagged one key part of testimony in the transcript released of the deposition by Ukraine embassy political officer David Holmes.
The transcript reveals Rep. Adam Schiff (D-CA), the former federal prosecutor who chairs the House Intelligence Committee, interviewing Holmes about Ukraine's desperation to set up a meeting with Trump.
‘Something nefarious going on’: Obama deputy chief of staff doesn’t buy White House claims on Trump’s health
The deputy chief of staff for operations in the Obama administration broke down on Monday why the White House claims on President Donald Trump's surprise Saturday visit to Walter Reed Hospital.
Jim Messina, who also was the campaign manager for Barack Obama's 2012 re-election campaign, was interviewed Monday on MSNBC's "The Last Word" by anchor Lawrence O'Donnell.
O'Donnell noted the note the White House physician sent to White House press secretary Stephanie Grisham:
[caption id="attachment_1563602" align="aligncenter" width="800"] Memorandum from Dr. Sean Conley to Stephanie Grisham.[/caption]
Trump doctor denies the president underwent any ‘neurologic evaluations’ at Walter Reed Hospital
The physician to the president claimed that President Donald Trump did not undergo "neurologic" evaluations during a surprise visit to Walter Reed Hospital.
White House press secretary Stephanie Grisham released a picture of a memorandum from Dr. Sean Conley, which was printed on "Office of the Press Secretary" letterhead.
The memo was sent to Grisham.
On Saturday, Grisham had claimed the purpose of the visit was to conduct a "partial" physical. Dr. Conley referred to the visit as an "interim check up."